Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) has issued an announcement.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has announced an estimated net profit for the first half of 2025, ranging from RMB1,840 million to RMB2,000 million, marking a significant year-on-year increase of 180% to 204%. However, when non-recurring gains or losses are excluded, the net profit is expected to decrease by 2% to 12%, ranging from RMB560 million to RMB620 million, compared to the same period in the previous year.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhongxin Pharmaceutical Group Corporation Limited, is incorporated in the People’s Republic of China. The company operates in the pharmaceutical industry, focusing on the development and production of pharmaceutical products.
For an in-depth examination of 2TZ stock, go to TipRanks’ Overview page.